The device helps reduce the need for remedial surgical procedures. Credit: Engin Akyurt from Pixabay.

ŌNŌCOR has entered an exclusive distribution agreement with B. Braun Interventional Systems (BIS) for its ŌNŌ retrieval device in the US. 

As part of the agreement, BIS will begin commercialisation activities for the device in the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The ŌNŌ device is intended to receive, align, compress and remove material (non-biologic and biologic) from the vascular system.

It is also compatible with commercially available endovascular snares, vascular sheaths and other graspers.

The device has been designed to reduce the need for remedial surgical procedures, as well as make catheter-based retrieval less tedious, quicker and safer.

See Also:

BIS upstream marketing and portfolio strategy director Peter Flosdorf said: “The ŌNŌ pushes the boundaries of how we can serve the needs of congenital and structural heart interventional cardiologists and the patients they treat.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ŌNŌCOR received clearance from the US Food and Drug Administration for the device in May 2022.

The device has since been utilised at select labs in the country.

The teams from both companies now plan a limited launch of the device later this year and the complete launch is planned for the PICS Society Annual Symposium next month.

ŌNŌCOR CEO Mark Piper said: “We are thrilled to have entered an agreement with BIS that will allow every interventionalist performing a catheter-based procedure to have an ŌNŌ device at hand.”